Citadel Advisors’s BioVie BIVI Stock Holding History

Citadel Advisors’s Portfolio BIVI Stock Details BIVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$186K	Buy	95,952 +50,660	+112%	+$79.6K	﹤0.01%	12148
2026 Q1	$63.4K	Buy	45,292 +27,142	+150%	+$34.9K	﹤0.01%	12301
2025 Q4	$21.1K	Sell	18,150 -86,381	-83%	-$139K	﹤0.01%	12334
2025 Q3	$199K	Buy	+104,531	New	+$423K	﹤0.01%	11275
2024 Q1	–	Hold	0	–	–	–	14569
2023 Q4	–	Sell	-81	Closed	-$24.3K	–	14154
2023 Q3	$27.5K	Buy	+81	New	+$31.7K	﹤0.01%	12359
2023 Q2	–	Sell	-16	Closed	-$10.8K	–	14349
2023 Q1	$12.9K	Sell	16 -136	-89%	-$90.1K	﹤0.01%	13385
2022 Q4	$118K	Buy	+152	New	+$82.2K	﹤0.01%	10990

Other funds holding BIVI

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Diametric Capital Boston, Massachusetts $948M AUM 47.49% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PTC

Philadelphia Trust Company Philadelphia, Pennsylvania $1.56B AUM 44.46% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

PCM

Prelude Capital Management New York $1.37B AUM 71.68% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Citadel Advisors's BIVI Position: Q2 2026 in Review

Citadel Advisors increased its BioVie (BIVI) stake by 112% in Q2 2026, buying an estimated $79.6K and bringing the position to 95,952 shares worth $186K. The position accounts for ﹤0.01% of the portfolio, ranked #12148.

Citadel Advisors first reported a position in BIVI in Q4 2022 and has held it in 7 quarters since. The position peaked at $199K in Q3 2025. 36 funds tracked by Wall St. Rank hold BIVI as of Q2 2026.

Citadel Advisors held 95,952 shares of BioVie worth $186K as of Q2 2026.
Citadel Advisors bought 50,660 BioVie shares in Q2 2026, an estimated $79.6K.
BioVie made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #12148 holding.
Citadel Advisors first reported a position in BioVie in Q4 2022 and has held it in 7 quarters since.
Citadel Advisors's BioVie position peaked at $199K in Q3 2025.
36 funds tracked by Wall St. Rank held BioVie as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.